BridgeBio Pharma, Inc. — Director's Dealing 2023

Sep 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-09-05

Reporting Person: Scott Randal W. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-05	Common Stock	S	2500	$30.00	Disposed	13500	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5000	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.

F2: By Thinking Bench Capital LLC.